77 related articles for article (PubMed ID: 25109334)
1. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylcysteine Alters Disease Progression and Increases Janus Kinase Mutation Frequency in a Mouse Model of Precursor B-Cell Acute Lymphoblastic Leukemia.
Sams MP; Iansavitchous J; Astridge M; Rysan H; Xu LS; Rodrigues de Oliveira B; DeKoter RP
J Pharmacol Exp Ther; 2024 Mar; 389(1):40-50. PubMed ID: 38336380
[TBL] [Abstract][Full Text] [Related]
3. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
5. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Liongue C; Ratnayake T; Basheer F; Ward AC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474223
[TBL] [Abstract][Full Text] [Related]
7. In vivo impact of JAK3 A573V mutation revealed using zebrafish.
Basheer F; Bulleeraz V; Ngo VQT; Liongue C; Ward AC
Cell Mol Life Sci; 2022 May; 79(6):322. PubMed ID: 35622134
[TBL] [Abstract][Full Text] [Related]
8. Identification of U937
Si H; Wang J; He R; Yu X; Li S; Huang J; Li J; Tang X; Song X; Tu Z; Zhang Z; Ding K
Front Oncol; 2021; 11():807200. PubMed ID: 35111683
[TBL] [Abstract][Full Text] [Related]
9. Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis.
Zhang C; Dang D; Cong L; Sun H; Cong X
Cancer Med; 2021 Jul; 10(14):4710-4720. PubMed ID: 34159752
[TBL] [Abstract][Full Text] [Related]
10. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
[TBL] [Abstract][Full Text] [Related]
11. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.
Carey A; Edwards DK; Eide CA; Newell L; Traer E; Medeiros BC; Pollyea DA; Deininger MW; Collins RH; Tyner JW; Druker BJ; Bagby GC; McWeeney SK; Agarwal A
Cell Rep; 2017 Mar; 18(13):3204-3218. PubMed ID: 28355571
[TBL] [Abstract][Full Text] [Related]
12. RNAi Screening of Leukemia Cells Using Electroporation.
Agarwal A; Tyner JW
Methods Mol Biol; 2016; 1470():85-94. PubMed ID: 27581286
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.
Simpson HM; Khan RZ; Song C; Sharma D; Sadashivaiah K; Furusawa A; Liu X; Nagaraj S; Sengamalay N; Sadzewicz L; Tallon LJ; Chen QC; Livak F; Rapoport AP; Kimball A; Banerjee A
PLoS One; 2015; 10(11):e0141906. PubMed ID: 26536348
[TBL] [Abstract][Full Text] [Related]
14. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
15. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
16. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
17. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
